Table 2.
Cumulative proportions of treatment success (adequate clinical and parasitological response) for each treatment arm at fixed time points in pregnant women
| Cumulative percentage of treatment success (95% CI) estimated by Kaplan-Meier method | p value | |||
|---|---|---|---|---|
| DP | ASMQ | AL+ | ||
| P. falciparum* PCR-corrected | N = 49 | N = 55 | N = 50 | 0.13 |
| Day 28 | 93.7% (81.6–97.9) | 81.5% (68.4–89.6) | 91.9% (79.8–96.9) | |
| Day 42 | 93.7% (81.6–97.9) | 81.5% (68.4–89.6) | 87.5% (74.3–94.2) | |
| Day 63 | 93.7% (81.6–97.9) | 79.6% (66.1–88.1) | 87.5% (74.3–94.2) | |
| Delivery | 93.7% (81.6–97.9) | 79.6% (66.1–88.1) | 87.5% (74.3–94.2) | |
| P. falciparum* PCR-uncorrected | N = 49 | N = 57 | N = 50 | 0.07 |
| Day 28 | 93.7% (81.6–97.9) | 80.4% (67.4–88.6) | 91.9% (79.8–96.9) | |
| Day 42 | 91.4% (78.7–96.7) | 80.4% (67.4–88.6) | 87.5% (74.3–94.2) | |
| Day 63 | 91.4% (78.7–96.7) | 78.5% (65.3–87.2) | 87.5% (74.3–94.2) | |
| Delivery | 91.4% (78.7–96.7) | 70.7% (53.8–82.4) | 84.6% (70.2–92.4) | |
| P. vivax* | N = 125 | N = 117 | N = 126 | 0.0006‡ |
| Day 28 | 100.0% | 100.0% | 95.8% (90.2–98.2) | |
| Day 42 | 98.3% (93.4–99.6) | 99.0% (93.2–99.9) | 79.3% (70.8–85.6) | |
| Day 63 | 82.9% (74.5–88.8) | 89.5% (81.4–94.2) | 68.5% (59.0–76.1) | |
| Delivery | 20.6% (5.1–43.4) | 46.0% (30.9–60.0) | 28.7% (10.0–50.8) | |
| Any malaria recurrence | N = 171 | N = 169 | N = 170 | 0.03‡ |
| Day 28 | 98.2% (94.6–99.4) | 92.5% (87.2–95.7) | 93.9% (88.9–96.6) | |
| Day 42 | 95.1% (90.4–97.5) | 90.6% (84.8–94.2) | 79.2% (72.0–84.7) | |
| Day 63 | 83.1% (76.1–88.2) | 80.8% (73.4–86.2) | 69.9% (62.0–76.4) | |
| Delivery | 37.3% (18.7–56.0) | 48.7% (37.3–59.2) | 43.7% (26.5–59.7) | |
AL+ artemether-lumefantrine extended regimen, ASMQ artesunate-mefloquine, CI confidence interval, DP dihydroartemisinin-piperaquine, PCR polymerase chain reaction
*Including co-infection of P. falciparum and P. vivax
p values by log-rank test or Wilcoxon test (‡). For all endpoints, + 3 days allowed